1 reports of this reaction
12.5% of all OCTINOXATE, OXYBENZONE reports
#6 most reported adverse reaction
OCULAR HYPERAEMIA is the #6 most commonly reported adverse reaction for OCTINOXATE, OXYBENZONE, manufactured by Carma Laboratories, Inc.. There are 1 FDA adverse event reports linking OCTINOXATE, OXYBENZONE to OCULAR HYPERAEMIA. This represents approximately 12.5% of all 8 adverse event reports for this drug.
Patients taking OCTINOXATE, OXYBENZONE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a frequently reported adverse event for OCTINOXATE, OXYBENZONE, accounting for a significant proportion of all reports.
In addition to ocular hyperaemia, the following adverse reactions have been reported for OCTINOXATE, OXYBENZONE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 1 FDA reports for OCTINOXATE, OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 12.5% of all adverse event reports for OCTINOXATE, OXYBENZONE, making it a notable side effect.
If you experience ocular hyperaemia while taking OCTINOXATE, OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.